You are here
P&T December 2014
The prices of some generic pharmaceuticals have lifted off into the stratosphere. A variety of reasons account for the increases, including loss of competition, dropping of product lines, and delays at the Food and Drug Administration.
Stem cell therapies offer great promise for a wide range of diseases and conditions. However, stem cell research—particularly human embryonic stem cell research—has also been a source of ongoing ethical, religious, and political controversy.
Antidiabetic agents can be delivered orally or with a syringe, but other options are also available, such as insulin and non-insulin pen devices and insulin pumps. This article reviews the available delivery devices and their current place in therapy.
Another tragic parenteral nutrition compounding error
FDA approvals, drug indications, and updates
Ledipasvir/sofosbuvir (Harvoni) for hepatitis C virus genotype 1 infection; dulaglutide (Trulicity) for glycemic control in type-2 diabetes; netupitant/palonosetron (Akynzeo) for prevention of nausea and vomiting related to chemotherapy; and naloxegol (Movantik) for opioid-induced constipation in patients with chronic noncancer pain
Ceftolozane/tazobactam: a new option in the treatment of complicated gram-negative infections
Sessions covered metastatic breast cancer, cachexia in non–small-cell lung cancer, recurrent and/or metastatic head and neck squamous-cell carcinoma, and melanoma.
Global prevalence of type-2 diabetes is expected to reach 330 million cases by 2022, with medication sales of $67.7 billion. The market is crowded with generic medications, and most products now in the development pipeline are “me-too” drugs.